64
Participants
Start Date
June 10, 2022
Primary Completion Date
March 7, 2023
Study Completion Date
May 26, 2023
NP-011 (Single Ascending Dose Phase)
The participants will receive assigned single dose of NP-011 after a minimum 8 hour fast on Day 1
NP-011 (Multiple Ascending Dose Phase)
The participants will receive assigned dose of NP-011 after a minimum 8 hour fast once daily for 7 days
NP-011 (Placebo)
The participants will receive single dose of NP-011 after a minimum 8 hour fast on Day 1 in Single Ascending Dose part and will receive once daily for 7 days after a minimum 8 hour fast in Multiple Ascending dose part of the study
CMAX Clinical Research Pty Ltd, Adelaide
Novotech (Australia) Pty Limited
INDUSTRY
Nexel Co., Ltd.
INDUSTRY